Charlotte’s Web Holdings Inc (OTCMKTS:CWBHF) has oddly lagged the broader CBD space during the bounce we have tracked in stocks related to the theme over recent days. To push back against the lackluster energy in the tape, the company just announced that The Vitamin Shoppe (NYSE: VSI), an omni-channel, specialty retailer of nutritional products, has commenced selling the new line of Charlotte’s Web CBD hemp extract-infused CBD gummies in 738 stores across 45 U.S. states.
According to the release, this expands Charlotte’s Web product offerings carried by The Vitamin Shoppe to include CBD hemp extract oil tinctures, liquid capsules, and now gummies. Charlotte’s Web gummies are a popular edible format providing measurable consumption of convenient bite-sized full-spectrum CBD hemp extract.
Charlotte’s Web Holdings Inc (OTCMKTS:CWBHF) develops and distributes hemp-based cannabidiol (CBD) wellness products. Its products include CBD hemp oils, capsules, topicals, and pet products that feature CBD hemp oil extracts.
Charlotte’s Web Holdings, Inc. sells its products online as well as through distributors, and brick and mortar retailers.
The company was formerly known as Stanley Brothers Holdings Inc. and changed its name to Charlotte’s Web Holdings, Inc. in July 2018. The company was incorporated in 2018 and is headquartered in Boulder, Colorado.
Charlotte’s Web Holdings, Inc. is the market leader in th production and distribution of innovative hemp-based cannabidiol wellness products. Founded by the Stanley Brothers, the Company’s premium quality products start with proprietary hemp genetics that are responsibly manufactured into whole plant hemp extracts naturally containing a full spectrum of phytocannabinoids, including CBD, terpenes, flavonoids and other beneficial hemp compounds. Industrial hemp products are non-intoxicating.
Charlotte’s Web current product categories include tinctures (liquid products), capsules, topical, as well as pet products. Charlotte’s Web hemp-based whole plant extracts are sold through select distributors, brick and mortar retailers, and online through the Company’s website.
Charlotte’s Web Holdings Inc (OTCMKTS:CWBHF) generated sales of $33.5M, according to information released in the company’s most recent quarterly financial report. That adds up to a sequential quarter-over-quarter growth rate of 16% on the top line. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($67.2M against $18.3M).
Medipharm Labs Corp (OTCMKTS:MEDIF) is another name worth a look as the tenor of the action shifts in the space. The company managed to rope in revenues totaling $22M in overall sales during the company’s most recently reported quarterly financial data — a figure that represents a rate of top line growth of 0%, as compared to year-ago data in comparable terms. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($8.6M against $35.7M, respectively).
Shares have been on the mend in recent trading sessions. Helping to possibly extend that fresh direction, the company just announced it successfully completed its second set of export shipments of medical cannabis concentrate, which were 137% greater in volume compared to its first export into Australia in June 2019. According to the release, “Through its wholly owned subsidiary, MediPharm Labs Inc., the Company received its second set of export permits from Health Canada to ship an increased volume of medical cannabis concentrates from Canada to Australia. Prior to the shipment, the Australian Government’s Office of Drug Control Section also issued a second set of import permits.”
Medipharm Labs Corp (OTCMKTS:MEDIF) focuses on producing pharma-grade cannabis oil and concentrates in Canada. It also focuses on providing cannabis contract processing services to licensed producers and growers; supplying cannabis oil to companies for sale under its brand; and supplying raw materials and processing for the creation of ready-to-sell cannabis products. The company was founded in 2015 and is headquartered in Barrie, Canada.
Founded in 2015, MediPharm Labs has the distinction of being the first company in Canada to become a licensed producer for cannabis oil production under the ACMPR without first receiving a cannabis cultivation license.
This expert focus on cannabis concentrates from our cGMP (current Good Manufacturing Practices) and ISO standard clean rooms and critical environments laboratory, allows MediPharm Labs to produce purified, pharmaceutical-grade cannabis oil and concentrates for advanced derivative products. MediPharm Labs has invested in an expert, research-driven team, state-of-the-art technology, downstream extraction methodologies and purpose-built facilities to deliver pure, safe and precisely-dosed cannabis products to patients and consumers. MediPharm Labs’ private label program is a high margin business for the company, whereby it opportunistically procures dry cannabis flower and trim from its numerous product supply partners, to produce proprietary cannabis oil concentrate products for resale globally on a private label basis.
Through its subsidiary, MediPharm Labs Australia Pty. Ltd., MediPharm Labs has also completed its application process with the federal Office of Drug Control to extract and import medical cannabis products in Australia.
“We are pleased to have completed our second set of shipments of medical cannabis concentrate into Australia in the third quarter as we look to participate in addressing the growing Australian medical patient demand,” said Pat McCutcheon, Chief Executive Officer, MediPharm Labs. “As international demand for purified cannabis concentrates continues to grow, we have focused on expanding our global supply chain and our international presence, including through our recently announced supply agreement for the German medical market. We have also focused on meeting diverse international regulatory and permitting requirements, including working towards our EU GMP, to grow export volumes of MediPharm Labs’ private-label concentrates.”
Trulieve Cannabis Corp (OTCMKTS:TCNNF) is another play in full bounce mode as we enter a fresh week of action. One of the key developments here was the stock’s pop above its key 50-day simple moving average, a breakout coming on above average volume.
That move comes in concert with the company’s most recent announcement, that it is set to open the doors of their record 37th Florida location on Thursday, October 3rd, in Cape Coral. According to the release, “Trulieve presently operates 36 other dispensaries throughout the State of Florida, including in the nearby communities of Fort Myers, Bonita Springs, and Venice. The storefront, located on Santa Barbara Boulevard in North Cape Coral, will advance the company’s mission to expand and ensure safe, reliable patient access statewide.”
Trulieve Cannabis Corp (OTCMKTS:TCNNF) engages in the cultivation, possession, distribution, and sale of medical cannabis in the United States. It offers a suite of Trulieve branded products with approximately 125 SKUs, including nasal sprays, capsules, concentrates, syringes, and cannabis flower in tamper-proof containers for vaporizers, topical creams, tinctures, and vape cartridges.
The company distributes its products to Trulieve branded stores (dispensaries) in Florida, as well as takes orders online and by phone for delivery. As of November 20, 2018, the company operated 21 dispensaries. Trulieve Cannabis Corp. is headquartered in Quincy, Florida.
Traders will note 15% added to share values of the company over the past month of action. What’s more, the company has registered increased average transaction volume recently, with the past month seeing 44% beyond what we have been seeing over the larger time frame.
“Patients are always the focus at Trulieve. As Florida’s registry grows and patients continue to seek natural relief, we will continue to expand patient access to the safe, reliable, and effective medications they have come to rely on,” said Trulieve CEO Kim Rivers. “We’re looking forward to educating patients on the process, from their first steps into medical cannabis to exploring new treatment options, and offering direct access for those who may not have had convenient access to a dispensary in the past.”If you’re long this stock, then you’re liking how the stock has responded to the announcement. TCNNF shares have been moving higher over the past week overall, pushing about 13% to the upside on above average trading volume.
Trulieve Cannabis Corp (OTCMKTS:TCNNF) pulled in sales of $77.5M in its last reported quarterly financials, representing top line growth of 157.6%. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($70.6M against $82.6M, respectively).